Who are AGN-199201's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SAR231893, ASC-01, "Raylis", HGP0608, MT-6548, AGN-151586.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/agn-199201.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AGN-199201 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AGN-199201 (AGN-199201) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective androgen receptor modulator (SARM). Area: Endocrinology / Musculoskeletal.

phase 3 Selective androgen receptor modulator (SARM) Androgen receptor (AR) Endocrinology / Musculoskeletal Small molecule Live · refreshed every 30 min

Target snapshot

AGN-199201 (AGN-199201) — Allergan. AGN-199201 is a selective androgen receptor modulator (SARM) that activates androgen signaling in target tissues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AGN-199201 TARGET	AGN-199201	Allergan	phase 3	Selective androgen receptor modulator (SARM)	Androgen receptor (AR)
SAR231893	SAR231893	Sanofi	marketed	Selective androgen receptor modulator (SARM)	Androgen receptor (AR)
ASC-01	ASC-01	Otsuka Pharmaceutical Co., Ltd.	phase 3	Selective androgen receptor modulator (SARM)	Androgen receptor (AR)
"Raylis"	"Raylis"	The Clinic of Men's Health and Couple Longevity, Russia	phase 3	Selective androgen receptor modulator (SARM)	Androgen receptor
HGP0608	HGP0608	Hanmi Pharmaceutical Company Limited	phase 3	Selective Androgen Receptor Modulator (SARM)	Androgen Receptor (AR)
MT-6548	MT-6548	Tanabe Pharma Corporation	phase 3	Selective Androgen Receptor Modulator (SARM)	Androgen Receptor (AR)
AGN-151586	AGN-151586	AbbVie	phase 3	Selective Androgen Receptor Modulator (SARM)	Androgen Receptor (AR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective androgen receptor modulator (SARM) class)

Allergan · 3 drugs in this class
Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class
Sanofi · 1 drug in this class
The Clinic of Men's Health and Couple Longevity, Russia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AGN-199201 — Competitive Intelligence Brief. https://druglandscape.com/ci/agn-199201. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing